Beyond the liver: a novel lipid library opening new horizons for LNP developers

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Lipid nanoparticles (LNPs) have emerged as a versatile platform for RNA delivery, finding extensive use in both in vivo and ex vivo applications such as prophylactic and therapeutic vaccines, gene editing, protein replacement therapies and genetically modified cell therapies. Despite their numerous advantages, LNPs still exhibit some limitations, notably their tendency to accumulate in the liver, causing loss of efficiency and off-target effects. Addressing this challenge is a top priority within the field, as it holds the key to unlocking the full therapeutic potential of these innovative treatments.

In this webinar, the utilization of an innovative library of imidazolium-based lipids in the formulation of LNPs will be showcased, highlighting their potential to fully replace or complement ionizable lipids.

Comprehensive characterization data of the LNPs produced (physical properties, encapsulation efficiency, and stability) will be presented. Additionally, our presenters will delve deeper into the benefits provided by different lipids from the library in various applications (e.g. vaccination, extrahepatic tropism, T cell engineering), in order to demonstrate the value of screening the library to identify the best suited lipid formulations for specific therapeutic objectives.

As a webinar attendee, you will gain insight on:

• A novel imidazolium-based lipid library: LipidBrick®
• The benefits of innovative lipids on the properties of LNPs, whether as a total replacement for the ionizable lipid or as a complement
• New horizons for RNA therapeutics developers seeking to cure extrahepatic diseases or avoid off-target hepatic effects

Ian Villamagna

Bioprocess Sales Specialist at Polyplus (now part of Sartorius)

Ian brings a distinctive blend of expertise in chemistry and physiology, leading to a thesis project focused on the development and delivery of polymeric nanoparticles to large animal models during his doctoral studies. Transitioning to industry, Ian spent nearly 4 years as a Field Application Scientist in the field of nanoparticles for RNA and DNA therapeutics. During this tenure, he guided numerous clients through the process of developing lipid nanoparticle-based drugs, leading them from early preclinical stages to clinical manufacture. Presently, Ian is the Sales Specialist, spearheading the in vivo DNA and RNA Therapeutics portfolio within the Advanced Therapy Solutions business unit at Sartorius.

Brooke Benson

Bioprocess Application Specialist at Polyplus (now part of Sartorius)

Brooke holds a BS in Bioengineering from the University of New Hampshire. Upon entering the field, she dedicated 2 years at nanoComposix, specializing in the synthesis of metallic nanomaterials for lateral flow assay development. Brooke then joined Nitto Biopharma, where she handled the development and implementation of a high-throughput screening platform for lipid nanoparticle (LNP) formulation. She is now the Bioprocess Application Specialist for in vivo DNA and RNA therapeutics within the Advanced Therapy Solutions business unit at Sartorius.

Watch now

SPEAKERS

Ian Villamagna

Bioprocess Sales Specialist at Polyplus (now part of Sartorius)

Brooke Benson

Bioprocess Application Specialist at Polyplus (now part of Sartorius)

You might also like

Development of an automated AAV capsid titer assay on a high-throughput platform

Matthew J.Lotti, John Chappell

3 September

in 39

Days

Register

Quickly and accurately measure key analytical attributes of viral vectors with macro mass photometry

Laura Pala

29 August

in 34

Days

Register

Extracellular vesicles: setting-up the path to IND with advanced characterization packages

Davide Zocco

28 August

in 33

Days

Register

Optimizing bioprocess purification: effective nucleic acid removal in high salt environments

Joanna Niska-Blakie, Eleonora Turco

22 August

in 27

Days

Register

Engineering next-generation CAR-T cell therapy for cancer

Yvonne Chen

21 August

in 26

Days

Register